Keppra Xr is owned by Ucb Inc.
Keppra Xr contains Levetiracetam.
Keppra Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Keppra Xr was authorised for market use on 12 September, 2008.
Keppra Xr is available in tablet, extended release;oral dosage forms.
The generics of Keppra Xr are possible to be released after 17 September, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7858122||UCB INC||Extended release formulation of levetiracetam|| |
(5 years from now)
Market Authorisation Date: 12 September, 2008
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic